Dogwood Therapeutics (DWTX) Corporate presentation summary

Corporate overview and leadership

• Headquarters in Atlanta, GA, listed on Nasdaq with ticker DWTX, 33.99M shares outstanding, and $13.2M cash as of March 31, 2026.

• Analyst coverage by H.C. Wainwright and Maxim Group.

• Executive team has experience developing blockbuster pain medicines such as Celebrex, Lyrica, Savella, and Cimzia.

Unmet medical need and market opportunity

• Over 3 million US patients suffer from chemotherapy-induced neuropathic pain (CINP), with 7.5 million experiencing painful neuropathy.

• CINP market across US, EU4/UK, and Japan is valued at $1B in 2025, projected to reach $3B by 2036.

• No FDA-approved treatments for CINP; current therapies include SNRIs, opioids, and tricyclic antidepressants.

Lead asset: Halneuron®

• Halneuron is a subcutaneous injection of tetrodotoxin (TTX), a selective Nav1.7 sodium channel blocker, preventing pain signal transmission without CNS effects.

• Demonstrated statistically significant and durable pain reduction in cancer and chemotherapy-related pain studies.

• Phase 2 studies showed 51% responder rate vs. 16% for placebo, with durable pain relief (mean 57.7 days for responders).

• Drop-out rate under 5% and manageable adverse events, mainly transient oral paresthesia.